- Conditions
- Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID, Long Covid19, Dyspnea, Orthostasis, Cognitive Impairment
- Interventions
- Comprehensive Rehabilitation, Augmented Usual Care
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 2,098
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma in Children, Asthma Chronic
- Interventions
- Asthma Ctrl+, Control
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Cincinnati, Ohio
- Conditions
- Covid19
- Interventions
- Not listed
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 6 Months to 120 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana
- Conditions
- Migraine
- Interventions
- CVT-427 (zolmitriptan inhalation powder)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas
- Conditions
- COPD, COPD Exacerbation
- Interventions
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 276
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Foley, Alabama + 178 more
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
- Interventions
- Steen Solution™, Conventional Lung Transplant
- Device · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Tachycardia, Dyspnea, COVID-19
- Interventions
- Metoprolol Succinate
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Pulmonary Disease, Chronic Obstructive, Heart Failure
- Interventions
- Pharmacist Counseling
- Procedure
- Lead sponsor
- Wilkes University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Scranton, Pennsylvania
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
- Conditions
- Education, Asthma, Obesity
- Interventions
- Collaborative Management in Pediatrics (CMP) Program
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 5
- States / cities
- Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- COPD
- Interventions
- Formoterol Fumarate
- Drug
- Lead sponsor
- Dey
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 52
- States / cities
- Jasper, Alabama • Phoenix, Arizona • Buena Park, California + 47 more
- Conditions
- Cancer
- Interventions
- therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Proactive Outreach, No Proactive Outreach
- Other
- Lead sponsor
- Harvard Medical School (HMS and HSDM)
- Other
- Eligibility
- Not listed
- Enrollment
- 19,113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts
- Conditions
- Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
- Interventions
- Med AAAction intervention
- Other
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee • Memphis, Tennessee
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg, BD MDI 320 μg, FF MDI 9.6 μg
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Rolling Hills Estates, California • Clearwater, Florida • Panama City, Florida + 14 more
- Conditions
- Asthma, Lung Function Decreased, Food Allergy, Allergic Sensitisation, Allergic Rhinitis, COPD, Atopy
- Interventions
- Dietary intake of various nutrients, foods and biocompounds
- Other
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 3,500 participants
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BEA 2180 BR, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 83 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 23 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- short chain fatty acid tracers
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 45 Years to 100 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Chronic Obstructive Airway Disease
- Interventions
- Bi-level positive airway pressure (BPAP), Oxygen, CPAP
- Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia (BPD)
- Interventions
- Not listed
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 36 Weeks to 37 Weeks
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
- Conditions
- Asthma, Asthma Chronic, Overweight and Obesity
- Interventions
- Metformin hydrochloride extended-release tablets, Visually identical placebo Metformin hydrochloride extended-release tablets
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Houston, Texas
- Conditions
- COPD
- Interventions
- Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
- Conditions
- COPD, Dyspnea, Hyperinflation
- Interventions
- Twice daily practice of device-guided slow breathing.
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota